BioMarin Provides Program Update on Vosoritide in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
BioMarin Provides Program Update on Vosoritide in Achondroplasia

New Data Shows Durable and Consistent Effects on Mean Annualized Growth Velocity for up to 12 months with Increases of 46%-65% from Baseline

Phase 3 Randomized Controlled Study Planned to Start at End of 2016

SAN RAFAEL, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) today provided an update on its Phase 2 study of vosoritide, an analog of C-type Natriuretic Peptide (CNP), in children with achondroplasia, the most common form of dwarfism.  After 12 months of daily dosing at 15 µg/kg/day, the cohort 3 patients (n=10) experienced a 46% or 1.9 cm/year increase in mean annualized growth velocity from baseline (p-value = 0.02). (See Table 2).  These findings provide evidence of durability of effect consistent with previously presented 6-month data for these patients, which demonstrated an annualized increase of 50% or 2.0 cm/year in mean annualized growth velocity.  In addition, 6-month data for 12 patients who were initiated on a lower dose and switched to 15 µg/kg/day showed an increase of 65% or 2.3 cm/year in mean annualized growth velocity from baseline (p-value = 0.002). 

Vosoritide at 15 µg/kg/day was well tolerated and there were no treatment-related serious adverse events or adverse events leading to discontinuation.  Consistent with the initial 6-month data, in the newly released data, all adverse events assessed as related to study drug were mild to moderate.  Over 12 months of dosing at 15 µg/kg/day, injection site reactions and hypotension (asymptomatic decreases in blood pressure) were the most common drug related adverse events, reported by 90% and 40% of cohort 3 patients, respectively.  All injection site reaction events were mild and the majority were resolved in one hour.  All adverse events of hypotension were mild, transient and resolved without intervention.  Safety data from lower dose cohort subjects who increased their dose to 15 µg/kg/day for at least 6 months was generally comparable to the 12-month safety data; however, two subjects experienced symptomatic events associated with a decrease in blood pressure, only one of which was deemed by the investigator to be related to study drug.  Both subjects continued to receive their daily dose of vosoritide without dose modification.  The phase 2 study is also evaluating a higher dose of 30 ug/kg/day.  Preliminary data after several months of treatment has shown that this dose is similarly well tolerated with no new safety findings.

A consistent effect in increasing urinary cyclic guanosine monophosphate (cGMP), a urinary pharmacodynamic biomarker, provides further evidence of durable pharmacologic activity of the 15 µg/kg/day dose over the 12-month observation period in cohort 3.   

“We’re encouraged by the consistency of the data from six to 12 months in both safety and efficacy, and plan to initiate a Phase 3 study by the end of the year,” said Hank Fuchs, MD, Chief Medical Officer at BioMarin.  “By addressing the root cause of achondroplasia with vosoritide treatment and normalizing annualized growth velocity in children with achondroplasia, we ultimately hope to improve the medical complications of disproportionate bone growth.”

“Children with achondroplasia are likely to experience a variety of medical complications caused by the condition,” said Ravi Savarirayan, M.D., Ph.D. Professor, Department of Paediatrics, University of Melbourne and Lead Investigator for the vosoritide Phase 2 study.  “A treatment like vosoritide has the potential to decrease medical complications and to increase function and quality of life.”

While the Phase 2 efficacy endpoint centers on mean annualized growth velocity, BioMarin hopes that that longer treatment may lead to improvement in many of the complications that can be associated with achondroplasia, such as disproportionality, though longer time of treatment and/or a controlled study may be required to demonstrate this effect.

By the end of 2016, BioMarin is planning to initiate a single Phase 3 randomized controlled study over 12 months in children with achondroplasia ages 5-14 with a subsequent long-term open-label extension subject to discussions with regulatory authorities.  In addition, BioMarin is planning a separate Phase 2 study evaluating the effect of vosoritide in infants and toddlers.  Vosoritide has Orphan designation in both the United States and Europe.  

Table 1:  Subject Disposition and Demographics

Category Cohort 3 (n=10) Cohorts 1 and 2 (n=12)*
Subjects Enrolled and Treated at 15 µg/kg/day 10 (100 %) 12 (100%
Subjects Who Completed 6 Months at 15 µg/kg/day 10 (100%) 12 (100%)
Subjects Who Completed 12 Months at 15 µg/kg/day 10 (100%) N/A
Age (years) at Enrollment    
Mean (SD) 8.0 (1.63) 7.6 (1.88)
Min, Max 6, 11 5, 10
Gender (n, %)    
Male 4 (40%) 6 (50%)
Female 6 (60%) 6 (50%)

*Subjects increased dose to 15 µg/kg/day after at least 6 months at 2.5 and/or 7.5 µg/kg/day;  4 of original 16 subjects in Cohorts 1 and 2 did not initiate dosing at 15 µg/kg/day due to subject decision to withdraw from the study (2), declining  extension study (1),  and growth plate closure (1)

Table 2:  Vosoritide Summary of Efficacy Results from Phase 2 Study in Children with Achondroplasia

Efficacy Analysis: Annualized Growth Velocity
Time Point 6 Months 12 Months ** 6 Months  
Annualized Growth Velocity Cohort 3 15 µg/kg/daily (n=10)   Cohort 3     15 µg/kg/daily (n=10)   Cohorts 1, 2 15 µg/kg/daily (n=12)  
Baseline      
     Mean (SD), cm/Year 4.0 (2.3) 4.0 (2.3) 3.6 (0.96)
Median   4.1     4.1     3.5  
Post-Treatment      
       
      Mean, (SD), cm/year 6.1 (1.1) 5.9 (0.92) 5.9 (1.6)
Median   5.9     5.6     5.6  
Change from Baseline      
       
      Mean (SD), cm/year 2.0 (2.0) 1.9 (2.0) 2.3 (1.9)
        Nominal p-value* 0.01     0.02   0.002
Percent increase from Baseline   50 %   46 %   65 %
       Based on means (%)      

* Nominal p-value, not adjusted for multiplicity ** Mean Annualized Growth Velocity change from baseline increases to 2.0 cm/year (50% increase) if one patient who missed majority of doses between 6 and 12 months is excluded

Phase 2 Study Design

Children in this study completed a minimum six month natural history 901 study to determine their respective baseline growth velocity prior to entering the Phase 2 study with vosoritide.   The Phase 2 trial was an open-label, sequential cohort dose-escalation study of vosoritide in children with achondroplasia.  In this three dose cohort study, patients were treated with either 2.5 µg/kg/daily, 7.5 µg/kg/ daily or 15 µg/kg/ daily, respectively.  A total of 26 children with achondroplasia with an average age of 7.8 years were enrolled in the study.  Based on the safety profile observed to date across the three dose cohorts, all subjects participating in the Phase 2 study were offered the dose of 15 µg/kg/daily during the 18 month extension study. An additional 9 patients were enrolled into a fourth cohort of  30 µg/kg/daily at the end of last year and initial growth velocity data from this cohort will be reported later this year.

About Achondroplasia  

Achondroplasia, the most common form of human dwarfism, is characterized by failure of normal conversion of cartilage into bone, which results in disproportionate short stature. This condition is caused by a mutation in the fibroblast growth factor receptor 3 gene (FGFR3), a negative regulator of bone growth. Beyond disproportionate short stature, people with achondroplasia can experience serious health complications, including foramen magnum compression, sleep apnea, bowed legs, mid-face hypoplasia, permanent sway of the lower back, spinal stenosis and recurrent ear infections. Some of these complications can result in invasive surgeries such as spinal cord decompression and straightening of bowed legs. In addition, studies show increased mortality at every age. [i] [ii]

More than 80% of children with achondroplasia have parents of average stature and have the condition as the result of a spontaneous gene mutation.  The worldwide incidence rate of achondroplasia is about one in 25,000 live births, per the World FactBook 2014 edition which translates into approximately 96,000 potential patients.  Vosoritide is being tested in children whose growth plates are still "open," typically those under 18 years of age.  This is approximately 25 percent of people with achondroplasia.  In the United States, Europe, Latin American and the Middle East, there is currently no licensed medicines for achondroplasia.

About BioMarin

BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.  

For additional information, please visit www.BMRN.com . Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the development of Vosoritide; the continued clinical development of vosoritide; the final results of the Phase 2 trial of vosoritide, the final results of the planned Phase 3 and Phase 2 studies and actions by regulatory authorities. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials of vosoritide; our ability to successfully manufacture vosoritide; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning vosoritide; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2015 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin ® is a registered trademark of BioMarin Pharmaceutical Inc.

[i] Hecht JT, Francomano CA, Horton WA, Annegers JF. Am J Hum Genet . 1987; 41: 454-464.

[ii] Wynn J, King TM, Gabello MJ, Waller DK, Hecht JT. Am J Med Genet A. 2007; 143A: 2502-2511.

Contact: Investors: Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media: Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451

Scroll down for more posts ▼

Top 10 Most Recent News Articles

CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 111

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 30

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
ELEGRP Makes Dyson Supersonic Global Voltage Ready

Updated Category News Views 36

Plugging Into the Future of Travel ELEGRP's latest move brings the Dyson Supersonic Travel hair dryer into the limelight, all decked out with global voltage compatibility. It's like the Swiss Army knife of hair dryers—one minute it’s working on 100V, next it’s flipping over to a juicy 240V, without breaking a sweat. The ALCI Difference: Safety Takes Center Stage...

Continue Reading
Veritran's Bold Move: Acquiring PrismaCampaigns Inc.

Updated Category News Views 0

Veritran's Strategic Leap Forward They're not messing around, folks. Veritran just made a power move by acquiring 100% of PrismaCampaigns Inc., and it’s more than just another day in the office. This marks a pivotal expansion of their American footprint, and they're zeroing in on our banks and credit unions with laser precision. Why This Matters for Financial...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 259

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 176

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
Avoid FOGs: Illinois Water's Holiday PSA

Updated Category News Views 0

Don't Ignore the Kitchen Sink This Holiday You ever poured something down the drain and just prayed it wouldn't come back to bite you later? Well, Illinois American Water is throwing up a big, red flag about doing exactly that during the holidays. When we're all busy passing the gravy boat and diving into festive feasts, it's easy to forget the after-party might just turn...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 151

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Parallels Desktop Tops 2026 Picks for Windows on Mac

Updated Category News Views 41

Diving into the Cross-Platform Conundrum Now, I've been in the trenches long enough to know that when companies start relying on Mac computers but can't ditch their essential Windows apps, they're bound to hit a digital brick wall. Picture this—accounting, enterprise management, all that jazz that still needs Windows to function. For those jumping between these two...

Continue Reading
Dr. Obeng Joins WellcomeMD with Special Offer for Patients

Updated Category News Views 23

New Beginnings in Concierge Medicine In late October, WellcomeMD opened its doors to Dr. Paa-Kofi Obeng—an arrival greeted with considerable anticipation in Richmond's medical scene. This isn't just any run-of-the-mill staff addition; Dr. Obeng brings with him over a decade of experience from places like the Veterans Administration Medical Center. He's armed with a...

Continue Reading

Top 5 Most Recently Viewed Articles

Ripplecoin Mining Unveils Revolutionary Cloud Mining App

Updated Category News Views 160

Introducing the Latest in Cloud Mining Technology Ripplecoin Mining has launched a state-of-the-art mobile application designed to enhance the cloud mining experience for cryptocurrency enthusiasts. Since its inception in 2017, Ripplecoin Mining has positioned itself as a leader in the industry. This exciting update allows users to effortlessly manage their cryptocurrency...

Continue Reading
AMSURG Centers Shine in National Human Experience Awards 2025

Updated Category News Views 108

AMSURG Centers Celebrate National Recognition AMSURG, a distinguished leader in ambulatory surgery center services, is thrilled to announce that three of its esteemed centers have been honored in the latest round of the Human Experience Awards. These awards, conferred by a renowned leader in healthcare experience solutions, aim to recognize organizations across the...

Continue Reading
Wynn Resorts Gains Momentum with Upgraded Growth Outlook

Updated Category News Views 276

Wynn Resorts got a jolt back in 2024 when Morgan Stanley raised its rating from Equal-weight to Overweight, pushing the price target up from $97 to $104. Traders perked up at the mention of a 25% upside, which suggested to many that there was solid potential brewing for those willing to take the plunge. Factors Driving the Upgrade: Opportunity Awaits This upgrade wasn't...

Continue Reading
Innovative Toilet Cleaning Solution for a Fresher Home

Updated Category News Views 117

Introducing the Sani Flush – A Revolution in Toilet Cleaning In the quest for cleaner and more sanitary bathroom experiences, a new invention has emerged. The Sani Flush - Toilet Refresher is designed to transform the way we think about toilet hygiene. Developed by a passionate inventor, this product offers a unique solution for maintaining cleanliness in toilet bowls...

Continue Reading
Understanding the Legal Rights of Fly-E Group Stakeholders

Updated Category News Views 205

Overview of Fly-E Group, Inc. Fly-E Group, Inc. is committed to revolutionizing sustainable transportation through its innovative electric vehicles powered by cutting-edge lithium battery technology. Investors in the company should stay informed about potential legal matters that may affect their investments, especially in light of recent events. Class Action Securities...

Continue Reading